ABSI vs ABCL โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ABCL Captures Institutional Edge (3โ1 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AbCellera Biologics Inc. Common Shares (ABCL) driven by superior Valuation, Growth & Margin, Momentum & Technical while ABSI counters with relative strength in Options & Structure. Fundamentally, ABSI trades at N/M Forward P/E with -9108.3% operating margin (-19.6% YoY revenue) versus ABCL at 27.6x Forward P/E and -1550.0% operating margin (-76.3% YoY). In options structure, ABSI sits in BREAKDOWN (15th %ile IV; Dealer Gamma Walls on Pro) against ABCL sits in CONSOLIDATION (25th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ABSI Revenue | ABCL Revenue | ABSI Op. Margin | ABCL Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | N/A | $10M | N/A | -35.5% | ABCL |
| FY2020 | $0M | $230M | -278.3% | 66.9% | ABCL |
| FY2021 | $0M | $380M | -1573.4% | 54.5% | ABCL |
| FY2022 | $10M | $490M | -1857.5% | 44.6% | ABCL |
| FY2023 | $10M | $40M | -2020.2% | -623.8% | ABCL |
| FY2024 | $0M | $30M | -2401.6% | -1091.7% | ABCL |
| FY2025 | $0M | $80M | -4297.0% | -289.0% | ABCL |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ABSI | ABCL | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.6B | $3.8B | Larger Scale | ABCL |
| Trailing P/E Ratio Valuation | N/M | 27.6x | Lower Multiple | ABCL |
| Forward P/E Ratio Valuation | N/M | 27.6x | Lower Multiple | ABCL |
| Revenue Growth (YoY) Growth | -19.6% | -76.3% | Higher Growth | ABSI |
| Operating Margin (TTM) Profitability | -9108.3% | -1550.0% | Higher Margin | ABCL |
| Net Profit Margin Profitability | 0.0% | -248.8% | Higher Margin | ABSI |
| Return on Equity (ROE) Capital Efficiency | -58.6% | -17.3% | Higher ROE | ABCL |
| 52-Week Range Position Momentum | 53% ($2โ$13) | 69% ($3โ$15) | Stronger Trend | ABCL |
| Beta / 30D Volatility Risk Regime | 3.31ฮฒ ยท 126% Vol | 2.31ฮฒ ยท 87% Vol | Lower Realized Risk | ABCL |
| Unified Institutional Score Composite Signal | 37.5 / 100 (SELL) | 60.7 / 100 (BUY) | Higher Composite | ABCL |